Skip to main content
. 2022 Jan 4;94(5):1950–1958. doi: 10.1002/jmv.27552

Table 2.

Comparison of laboratory parameters on Day 5 of treatment between the groups

Group 1 (n = 60), mean ± SD Group 2 (n = 60), mean ± SD Group 3 (n = 60), mean ± SD p
WBC (/µl) 8602. 3 ± 2676.9 8352.7 ± 2538.2 8895.1 ± 3867.8 0.51
Lymphocytes (/µl) 1102. 4 ± 874.2 1283.7 ± 857.6 1305.9 ± 733.3 0.85
Neutrophils (/µl) 6643.1 ± 2403.4 6485.7 ± 2110.2 7063.8 ± 3786.8 0.46
Eosinophils (/µl) 12.4 ± 20.1 11.7 ± 28.8 13.8 ± 26.1 0.76
Hemoglobin (g/L) 13.4 ± 1.1 13.1 ± 1.8 13.6 ± 2.1 0.52
Platelets (/µl) 268 920.1 ± 101 000 2 783 66.7 ± 96 432.1 281 750 ± 119 759.7 0.85
MPV (fl) 10.7 ± 0.7 10.8 ± 1.2 10.3 ± 0.8 0.09
AST (U/L) 31.4 ± 30.1 33.8 ± 32.7 28.4 ± 12.7 0.38
ALT (U/L) 58.4 ± 40.4 60.2 ± 44.7 45.9 ± 28.5 0.15
GGT (U/L) 72.4 ± 60.2 80.6 ± 96.2 52.1 ± 52.3 0.21
ALP (U/L) 71.4 ± 60.4 85.9 ± 58.9 66.8 ± 23.6 0.1
LDH (U/L) 301.4 ± 120.4 227.9 ± 60.2 269.8 ± 106.9 0.04a
Total protein (g/l) 58.9 ± 10.4 61.9 ± 7.4 59.9 ± 6.3 0.45
Albumin (g/l) 39.7 ± 9.5 40.8 ± 6.6 39.6 ± 4.9 0.36
Total bilirubin (mg/dl) 0.6 ± 0.2 0.5 ± 0.3 0.6 ± 0.3 0.61
Direct bilirubin (mg/dl) 0.3 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 0.78
Ferritin (ng/ml) 410.4 ± 214.6 345.2 ± 355.7 289.2 ± 292.8 0.5
Fibrinogen (ng/ml) 510.4 ± 110.1 405.4 ± 109.4 332.4 ± 72.1 0.002a
0.02b
D‐dimer (ng/ml) 678.3 ± 300.4 589.7 ± 527.1 476.4 ± 205.7 0.05a
Troponin‐ı (ng/dl) 4.1 ± 3.2 3.3 ± 1.9 4.4 ± 5.5 0.21
INR 1.2 ± 0.9 1.1 ± 0.1 1.1 ± 0.3 0.31
PT (s) 14.4 ± 1.7 13.8 ± 1.5 14.1 ± 2.1 0.44
aPTT (s) 28.4 ± 4.4 27.8 ± 2.8 28.9 ± 3.1 0.36
CRP (mg/l) 30.4 ± 20.4 12.6 ± 11.3 16.8 ± 18.3 0.03a
Procalcitonin (ng/ml) 0.8 ± 0.5 0.3 ± 0.4 0.4 ± 0.4 0.04a

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; GGT, γ‐glutamyl transferase; INR, international normalized ratio; LDH, lactate dehydrogenase; MPV, mean platelet volume; PT, prothrombin time; WBC, white blood cells.

a

Groups 2 and 3 versus Group 1.

b

Group 2 versus Group 3.